Followers | 249 |
Posts | 13655 |
Boards Moderated | 0 |
Alias Born | 05/19/2015 |
Saturday, August 13, 2022 8:48:57 PM
Some will try anything to try and get others not to buy RGBP!
Even when they know they can stop this gem of a stock with all its great patents! Even the naked short and distort Fudpucker MM’s that have been heavily Naked shorting RGBP have not managed to stop this latest Run.
Dr. David KOO’s is a Business Leader and has always put together a great team the Ichims being the cream of the crop!
KOO’s owns 38+% or 169+ million shares of RGBP preferred shares RGBPP!
https://www.nasdaq.com/press-release/regen-biopharma-inc.-files-provisional-patent-application-on-second-generation
Dr. David KOO’s has 169 Million reasons for making RGBP Great Again!
KOO’s owns 169+ million shares of RGBPP preferred shares or 169 million reasons to see that RGBP is successful.
https://www.marketscreener.com/business-leaders/David-Raymond-Koos-06H0YV-E/biography/
Check it out RGBP on the Fast Track!
Things looking up here:
San Diego, CA, March 30, 2022: Regen BioPharma, Inc. received communication from the U.S. Patent Office that certain claims in its application #15/820,324 entitled, “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans” have been allowed. $RGBP $RGBPP 1:39 PM · Mar 30, 2022·[/b
]
San Diego, CA, March 30, 2022: Regen BioPharma, Inc. received communication from the U.S. Patent Office that certain claims in its application #15/820,324 entitled, “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans” have been allowed.$RGBP $RGBPP
— Regen BioPharma Inc. (@TheRegenBio) March 30, 2022
On the next Big Fun RGBP Run with the right News, Deal, Partner or Buyout RGBP should get get the mother of all the RGBP Naked Short Squeezes IMO!
Now RGBP has much more going for us!
Regen BioPharma Inc's Company Profile
Business Description
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Anyone can contact KOO’s but you have to leave a call back number that helps keep the Bull $hitters that don’t want to be identified from wasting his time!
Telephone: (619) 722-5505 ext: 800
Fax: (619) 330-2328
Email: david.koos@regenbiopharma.com
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM